Morgan Stanley Maintains Overweight on Rhythm Pharmaceuticals, Lowers Price Target to $54
Morgan Stanley maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Overweight and lowers the price target from $57 to $54.
B of A Securities Downgrades Rhythm Pharmaceuticals to Underperform, Lowers Price Target to $17
B of A Securities analyst Tazeen Ahmad downgrades Rhythm Pharmaceuticals (NASDAQ:RYTM) from Neutral to Underperform and lowers the price target from $33 to $17.
Ladenburg Thalmann Downgrades Rhythm Pharmaceuticals to Neutral
Ladenburg Thalmann analyst Michael Higgins downgrades Rhythm Pharmaceuticals (NASDAQ:RYTM) from Buy to Neutral.
The Daily Biotech Pulse: Pfizer’s Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 3)
The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly’s Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 2)
Earnings Scheduled For August 3, 2021
Companies Reporting Before The Bell
• Myriad Genetics (NASDAQ:MYGN) is likely to report earnings for its fourth quarter.
• Stellantis (NYSE:STLA) is expected to report earnings for its second quarter.
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies.
Rhythm Pharma’s Imcivree Gets European Approval For Obesity, Control of Hunger Associated With Genetic Mutations
The European Commission (EC) has approved Rhythm Pharmaceuticals Inc’s (NASDAQ:RYTM) Imcivree (setmelanotide) for obesity and the control of hunger. The approval…
Rhythm Pharmaceuticals Announces European Commission Authorization Of IMCIVREE For Treatment Of Obesity And Control Of Hunger Associated POMC, PCSK1 And LEPR Deficiency
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced that the European